2025-04-09
NextCell’s CSO elected Vice President Elect for ISCT Europe
NextCell Pharma AB ("NextCell") announces that Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, has been elected Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT). The role is a key position within the organisation’s global leadership, offering significant influence over the future direction of cell and gene therapies, both across Europe and internationally.
Read moreRead more2025-04-07
Subgroup Analysis: NextCell Presents Preliminary One-Year Results from the Older Age Group in ProTrans-Young
NextCell Pharma today announces preliminary one-year results from the older age group (12–21 years) in the ongoing clinical trial ProTrans-Young. The study is evaluating the safety and efficacy of the company’s cell therapy, ProTrans, in preserving insulin production in young individuals newly diagnosed with type 1 diabetes, compared with placebo. The current analysis is an administrative subgroup analysis of the first 30 randomised patients, all included within six months of diagnosis – a favourable time point, as more insulin production is typically still present and can be preserved. However, variability in disease progression is greater early after diagnosis and during puberty, which at this stage makes interpretation of the treatment effect more challenging. A clearer effect is expected over time.
Read moreRead more2025-03-28
NextCell’s CSO Appointed to the Board of ATMP Sweden
NextCell Pharma AB ("NextCell") proudly announces that the company’s Chief Scientific Officer (CSO), Dr. Lindsay Davies, has been appointed to the board of ATMP Sweden. This further reinforces both her role and NextCell’s position as a key player in the development of advanced therapies, both nationally and internationally.
Read moreRead more2025-03-19
Recognition for NextCell’s CSO from the International Society of Cell and Gene Therapy
NextCell Pharma AB ("NextCell" or "the Company") announces that its CSO, Lindsay Davies, has been asked to lead the inaugural International Society of Cell and Gene Therapy (ISCT) industry committee for Europe and has been nominated as Vice President Elect in the 2025 ISCT elections.
Read moreRead more2025-03-13
Results from the Older Age Cohort in the ProTrans-Young Paediatric Study Expected in Aprilv
NextCell Pharma AB ("NextCell" or "the Company") announces that the last patient in the older age cohort (12–21 years) of the clinical Phase II study, ProTrans-Young, has now completed their 12-month follow-up. The collected data is currently being compiled, and an administrative subgroup analysis is planned to be presented at the IDF World Diabetes Congress in Bangkok from April 7–10.
Read moreRead more2025-02-19
All Patients with Severe Virus-Induced Pneumonia Treated in the ProTrans V Study
NextCell Pharma AB ("NextCell") announced today that all patients in the clinical trial ProTrans V, where ProTrans is used for the treatment of severe virus-induced pneumonia, have been treated. The study is being conducted at Örebro University Hospital and includes a total of nine patients, with three patients in each dose group.
Read moreRead more2025-01-30
NextCell Pharma publish Interim Report 1 2024/2025
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2024 – November 30, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
Read moreRead more2024-12-17
Long-term Effects with Repeated ProTrans Treatment After 6 Years
NextCell Pharma AB reports new results from the ProTrans-Repeat study, where type 1 diabetes patients have been followed for 5 years after receiving two doses of the stromal cell product ProTrans, in total 6 years after the first infusion. The results show that two out of three patients in the high-dose group increased their insulin production by 23% and 34% respectively.
Read moreRead more